Linn Woelber

Universität Hamburg — Germany

Medicine · Health Sciences

32h-index4.8kcitations161works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cervical Cancer and HPV Research(88), Endometrial and Cervical Cancer Treatments(69), Ovarian cancer diagnosis and treatment(26), Colorectal and Anal Carcinomas(25), Genital Health and Disease(13)

Publications160 total

Photodynamic therapy for high-grade squamous intraepithelial lesions: A randomized controlled trial
Med·2025· 2 citedOpen Access
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study
Gynecologic Oncology·2025Open Access
Anogenital high-risk HPV prevalence and screening considerations in female transplant recipients: a cross-sectional study
BMC Women s Health·2025Open Access
10O Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)
ESMO Open·2025Open Access
Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes.
Journal of Clinical Oncology·2025
Prognosis of isolated groin recurrence following sentinel lymph node biopsy in primary node-negative vulvar cancer.
Journal of Clinical Oncology·2025Open Access
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study
Journal for ImmunoTherapy of Cancer·2025· 8 citedOpen Access
Risk for Non-Sentinel Metastases in the Contralateral Groin in Patients with a Unilateral Positive Sentinel Lymph Node in Primary Vulvar Cancer- a Subgroup Analysis of the Ago-Vop.2 Qs Vulva Study
SSRN Electronic Journal·2025Open Access
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM
Brachytherapy·2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
International Journal of Gynecological Cancer·2024· 2 citedOpen Access
APL-1702 long-term efficacy and safety for cervical histologic, high-grade squamous intraepithelial lesions: Results from a randomized, phase III, global study
Gynecologic Oncology·2024· 1 cited
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study
Gynecologic Oncology·2024
BEATcc (ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030): A randomized phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer
Gynecologic Oncology·2024
Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG)
Geburtshilfe und Frauenheilkunde·2024
Prognosis of nodal recurrence following sentinel lymph node biopsy in primary node-negative vulvar cancer
Geburtshilfe und Frauenheilkunde·2024
Pre-operative CTCs in HGSOC patients as marker for identification of high-risk surgery candidates
Geburtshilfe und Frauenheilkunde·2024
Systematic review – Adjuvant radiotherapy of the vulva in primary vulvar cancer
Gynecologic Oncology·2024Open Access
Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG)
Journal of Cancer Research and Clinical Oncology·2024· 3 citedOpen Access
3560: A Phase 3 Study of Pembrolizumab + Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Radiotherapy and Oncology·2024
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer
2024· 1 cited
page 1 of 8Next →

Frequent Co-authors

Sven� Mahner(21), Matthias Choschzick(13), Fritz Jaenicke(13), Sven Mahner(10), Fabian Trillsch(10), Katharina Prieske(10), Donata Grimm(10), Christine zu Eulenburg(9), Elmar A. Joura(8), Felix Hilpert(8), Peter Hillemanns(8), Annette Hasenburg(7), Cordula Petersen(7), Friederike Gieseking(7), Joerg Schwarz(7), Nikolaus de Gregorio(6), Jalid Sehouli(6), Klaus Baumann(6), Barbara Schmalfeldt(6), Olaf Reich(6)